Thomas Erker Selected Research

Bumetanide (Bumex)

1/2020	Functional characterization of novel bumetanide derivatives for epilepsy treatment.
1/2020	Role of NKCC1 Activity in Glioma K+ Homeostasis and Cell Growth: New Insights With the Bumetanide-Derivative STS66.
1/2020	Impaired chloride homeostasis in epilepsy: Molecular basis, impact on treatment, and current treatment approaches.
1/2019	A Novel Na+-K+-Cl- Cotransporter 1 Inhibitor STS66* Reduces Brain Damage in Mice After Ischemic Stroke.
1/2017	Multiple blood-brain barrier transport mechanisms limit bumetanide accumulation, and therapeutic potential, in the mammalian brain.
1/2016	The bumetanide prodrug BUM5, but not bumetanide, potentiates the antiseizure effect of phenobarbital in adult epileptic mice.
1/2016	The search for NKCC1-selective drugs for the treatment of epilepsy: Structure-function relationship of bumetanide and various bumetanide derivatives in inhibiting the human cation-chloride cotransporter NKCC1A.
1/2015	Bumetanide is not capable of terminating status epilepticus but enhances phenobarbital efficacy in different rat models.
4/2014	A novel prodrug-based strategy to increase effects of bumetanide in epilepsy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Thomas Erker Research Topics

Disease

10	Neoplasms (Cancer) 12/2016 - 05/2002
8	Breast Neoplasms (Breast Cancer) 04/2013 - 07/2010
6	Epilepsy (Aura) 01/2020 - 10/2011
5	Leukemia 05/2015 - 03/2005
3	Seizures (Absence Seizure) 01/2020 - 01/2016
2	Brain Diseases (Brain Disorder) 01/2017 - 01/2016
2	Inflammation (Inflammations) 11/2014 - 01/2007
1	Glioma (Gliomas) 01/2020
1	Infarction (Infarctions) 01/2019
1	Ischemic Stroke 01/2019
1	Brain Injuries (Brain Injury) 01/2019
1	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 01/2019
1	Autistic Disorder (Autism) 01/2017
1	Necrosis 12/2016
1	Adenocarcinoma of Lung 01/2016
1	Ototoxicity 01/2016
1	Adenocarcinoma 01/2016
1	Drug-Related Side Effects and Adverse Reactions 09/2015
1	Myocardial Infarction 08/2015
1	Hypoxia (Hypoxemia) 05/2015
1	Lymphoma (Lymphomas) 02/2015
1	Status Epilepticus (Complex Partial Status Epilepticus) 01/2015
1	Traumatic Brain Injuries (Traumatic Brain Injury) 04/2014
1	Nervous System Diseases (Neurological Disorders) 04/2014
1	Alzheimer Disease (Alzheimer's Disease) 08/2012
1	Carcinoma (Carcinomatosis) 01/2012
1	Parkinson Disease (Parkinson's Disease) 10/2011
1	Hypertrophy 04/2011
1	Pancreatic Neoplasms (Pancreatic Cancer) 10/2009
1	Colonic Neoplasms (Colon Cancer) 06/2008
1	Cardiovascular Diseases (Cardiovascular Disease) 11/2007
1	Atherosclerosis 11/2007
1	Prostatic Neoplasms (Prostate Cancer) 09/2007
1	Carcinogenesis 01/2007

Drug/Important Bio-Agent (IBA)

9	Bumetanide (Bumex)FDA LinkGeneric 01/2020 - 04/2014
9	ResveratrolIBA 11/2014 - 03/2005
8	Proteins (Proteins, Gene)FDA Link 01/2017 - 07/2010
6	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 04/2013 - 05/2002
4	Pharmaceutical PreparationsIBA 01/2020 - 02/2015
4	ChloridesIBA 01/2020 - 04/2014
4	Sodium-Potassium-Chloride SymportersIBA 01/2019 - 04/2014
4	StilbenesIBA 01/2016 - 10/2006
4	Ribonucleotide Reductases (Ribonucleotide Reductase)IBA 10/2009 - 10/2006
3	tariquidar (XR9576)IBA 04/2013 - 08/2010
3	ElacridarIBA 04/2013 - 04/2011
3	DNA (Deoxyribonucleic Acid)IBA 10/2009 - 03/2005
2	Angiotensin IIIBA 01/2019 - 04/2011
2	ProdrugsIBA 01/2019 - 04/2014
2	Sodium Potassium Chloride Symporter Inhibitors (Loop Diuretics)IBA 01/2017 - 01/2016
2	Protein Isoforms (Isoforms)IBA 01/2017 - 01/2016
2	Phenobarbital (Luminal)FDA Link 01/2016 - 01/2015
2	CurcuminIBA 05/2015 - 01/2007
2	AntioxidantsIBA 04/2011 - 09/2006
2	EnzymesIBA 10/2009 - 10/2006
2	Cytarabine (Cytosar-U)FDA LinkGeneric 11/2007 - 03/2005
2	3,3',4,4',5,5'-hexahydroxystilbeneIBA 10/2006 - 09/2006
1	Pentylenetetrazole (Metrazol)IBA 01/2020
1	gamma-Aminobutyric Acid (GABA)IBA 01/2020
1	Temozolomide (Temodar)FDA LinkGeneric 01/2020
1	Benzoates (Benzoate)IBA 01/2019
1	Proline (L-Proline)FDA Link 01/2019
1	Alanine (L-Alanine)FDA Link 01/2019
1	BenzenesulfonamidesIBA 01/2019
1	Phosphotransferases (Kinase)IBA 01/2019
1	AnionsIBA 01/2017
1	Peptides (Polypeptides)IBA 01/2017
1	Histones (Histone)IBA 12/2016
1	CaspasesIBA 12/2016
1	CationsIBA 01/2016
1	Estrogen ReceptorsIBA 01/2016
1	Parasympatholytics (Antispasmodics)IBA 01/2016
1	Estrogens (Estrogen)FDA Link 01/2016
1	Estrogen Receptor alphaIBA 01/2016
1	Transcription Factors (Transcription Factor)IBA 05/2015
1	fludarabineIBA 02/2015
1	Chalcone (Benzalacetophenone)IBA 02/2015
1	BenzodiazepinesIBA 01/2015
1	DiureticsIBA 04/2014
1	4-oxo-4H-chromene-2-carboxylic acid (2- (2- (4- (2- (6,7- dimethoxy- 3,4- dihydro- 1H- isoquinolin- 2- yl)- ethyl)- phenyl)- 2H- tetrazol- 5- yl)- 4,5- dimethoxyphenyl)amideIBA 12/2012
1	ButyrylcholinesteraseIBA 08/2012
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2012
1	Verapamil (Calan)FDA LinkGeneric 01/2012
1	ATP-Binding Cassette Transporters (ABC Transporters)IBA 10/2011
1	Multidrug Resistance-Associated ProteinsIBA 10/2011
1	Adenosine Triphosphate (ATP)IBA 10/2011
1	Epidermal Growth Factor (EGF)IBA 04/2011
1	PolyphenolsIBA 10/2009
1	Nitric Oxide Synthase Type III (Endothelial Nitric Oxide Synthase)IBA 11/2007
1	N- hydroxy- N'- (3,4,5- trimethoxyphenyl)- 3,4,5- trimethoxy- benzamidineIBA 11/2007
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 11/2007
1	Biological ProductsIBA 09/2007
1	Hormones (Hormone)IBA 09/2007
1	Cyclooxygenase 1IBA 01/2007
1	3,3',4,5'-tetrahydroxystilbeneIBA 09/2006
1	tiazofurinIBA 03/2005
1	CytidineIBA 03/2005

Therapy/Procedure

1	Therapeutics 01/2019
1	Emergency Treatment 08/2015
1	PET protocol 11/2012
1	Combination Drug Therapy (Combination Chemotherapy) 03/2005